Platinum Virtual Sponsor
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Through our work in Biopharmaceuticals, we want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. There remains a huge unmet need in treating people with chronic diseases. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.
We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We think differently about the underlying genetic causes of cancer. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.
Gold Virtual Sponsor
Pfizer is one of the world's premier innovative biopharmaceutical companies, discovering, developing and providing over 170 different medicines and vaccines healthcare products to help improve the lives of millions of people in the UK and around the world every year.
Our purpose is grounded in our belief that all people deserve to live healthy lives. This drives our desire to provide medicines that are safe and effective.
After more than 170 years of treating and preventing disease, we’ve arrived at a new era; time of extraordinary focus on our science and the value it brings to people around the world.
Around the world, we strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of medicines and vaccines that have the potential to save lives, prevent illness and improve health and wellbeing.
But we don’t achieve this alone. Collaborations with healthcare providers, patient communities, academia, and policy makers are fundamental to bringing new medicines to patients.
We focus our efforts in six core areas where we are best positioned to develop medicines for much needed therapies.
Anti-infectives, Inflammation and Immunology, internal medicine, Oncology, Rare Disease and vaccines.
ACT Genomics® is an innovation-driven cancer solution provider in Asia with offices in Taipei, Hong Kong, Singapore & Tokyo. With our Next-Generation Sequencing (NGS) technology, CAP accredited laboratories, experienced bioinformatics team and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, and cancer risk assessment to medical professionals.
Our team is specialized in biomarker identification, underlying disease mechanism discovery and genetic alteration exploration. Pharmaceutical communities also benefit from our expertise in identifying targets for drug development, stratifying patients for clinical studies and delineating drug responses with efficiency and efficacy. We also take part in various international precision medicine biomarker programs, such as the TMB and HRD Harmonization Programs led by FOCR in the United States. Together we “Turn Genomics into Action”.
Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes, and MI Transcriptome™ whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market.
Caris is also advancing precision medicine with Caris Artificial Intelligence, combining its market leading service offering, Caris Molecular Intelligence® with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.
IPS Genomix stands for innovation that benefits to the community. Specialized in the latest prognostic, predictive and personalized medicine, IPS Genomix gives treating physicians access to important and clinically relevant genomic information further to testing human specimens (tissue, blood, saliva, buccal swab…) in the European or US partnering laboratories accredited and specialized in this field.
The treating physician can then individualize the treatment of his/her patients to enhance the prevention and/or treatment of certain conditions and diseases. IPS Genomix brings this intelligent and ground-breaking new solution to treating physicians and their patients in the Middle East and Africa thanks to partnerships with multinational companies.
Given the rapid evolution of this particular field, IPS Genomix constantly incorporates new technology platforms and assays to offer physicians and their patients with the most up to date, reliable and cutting-edge personalized medicine tools.